Please assess the completion status of the following clinical trial:

Trial Title: A Study of the Safety and Effectiveness of ADX-N05 in the Treatment of Excessive Daytime Sleepiness

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of narcolepsy~* Good general health~* Willing and able to comply with the study design and schedule and other requirements~Exclusion Criteria:~* If female, pregnant or lactating~* Customary bedtime later than midnight~* History of significant medical condition, behavioral or psychiatric disorder (including suicidal ideation), or surgical history~* Any other clinically relevant medical, behavioral or psychiatric disorder other than narcolepsy that is associated with excessive sleepiness~* History of significant cardiovascular disease~* Body mass index \>34~* Excessive caffeine use - \> 600 mg/day of caffeine or \> 6 cups of coffee/day~* History of alcohol or drug abuse within the past two years~* Nicotine dependence that has an affect on sleep

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Placebo, Then ADX-N05 (Type: EXPERIMENTAL): Participants first receive a placebo to match ADX-N05 once a day for 2 consecutive weeks (Weeks 1 and 2). They will then receive ADX-N05 150 mg tablet once a day for seven days (Week 3) followed by 300 mg (2 tablets) once a day for seven days (Week 4).
- ADX-N05, Then Placebo (Type: PLACEBO_COMPARATOR): Participants first receive ADX-N05 150 mg tablet once a day for seven days (Week 1) followed by 300 mg (2 tablets) once a day for seven days (Week 2). They will then receive a placebo to match ADX-N05 once a day for 2 consecutive weeks (Weeks 3 and 4).

Based on this trial design, predict the completion outcome and termination type (if applicable).